

Supplementary Table 1. Full list of CSF analysis and RT-QuIC positivity of 81 CSF of sCJD patients in Korea

No.	Age (yr)/Sex	14-3-3 protein	Total tau (pg/mL)	RT-QuIC*
1	70/M	Positive	117	N (0/4)
2	75/M	Positive	30	N (0/4)
3	27/F	Positive	475	N (0/4)
4	79/F	Positive	1,092	P (3/4)
5	48/F	Positive	3,158	P (3/4)
6	66/M	Positive	1,203	N (0/4)
7	82/M	Positive	5,248	P (4/4)
8	71/M	Positive	2,290	P (1/4)
9	50/M	Positive	3,182	N (0/4)
10	50/M	Positive	3,954	P (4/4)
11	66/F	Positive	4,260	P (3/4)
12	64/M	Positive	14,813	P (1/4)
13	63/F	Positive	11,386	P (1/4)
14	68/F	Positive	18,900	P (4/4)
15	73/M	Positive	7,362	P (4/4)
16	67/M	Positive	19,604	N (0/4)
17	54/F	Positive	6,098	P (4/4)
18	56/M	Positive	4,186	P (4/4)
19	42/F	Positive	7,641	N (0/4)
20	72/F	Positive	600	N (0/4)
21	47/M	Positive	2,987	P (4/4)
22	61/F	Positive	4,892	P (4/4)
23	76/M	Positive	8,341	P (4/4)
24	66/M	Positive	2,907	P (3/4)
25	51/M	Positive	2,257	P (2/4)
26	63/F	Positive	1,517	P (3/4)
27	43/F	Positive	1,514	N (0/4)
28	74/M	Positive	21,996	N (0/4)
29	72/M	Positive	930	P (4/4)
30	75/M	Positive	1,016	P (3/4)
31	80/F	Positive	3,525	P (4/4)
32	79/M	Positive	5,961	P (3/4)
33	70/F	Positive	3,049	P (4/4)
34	62/M	Positive	3,774	N (0/4)
35	39/F	Positive	1,839	P (4/4)
36	73/M	Positive	15,825	P (2/4)
37	73/M	Positive	3,959	P (3/4)
38	56/M	Positive	2,289	P (4/4)
39	58/M	Positive	8,127	P (4/4)
40	76/M	Positive	4,801	P (2/4)
41	69/M	Positive	20,529	P (4/4)
42	60/M	Positive	9,994	P (2/4)
43	76/M	Positive	9,763	P (3/4)
44	57/F	Positive	14,264	P (4/4)
45	65/M	Positive	19,234	P (4/4)
46	70/M	Positive	14,213	P (4/4)
47	54/F	Positive	34,772	P (3/4)
48	77/M	Positive	1,469	N (0/4)

Supplementary Table 1. Full list of CSF analysis and RT-QuIC positivity of 81 CSF of sCJD patients in Korea (continued)

No.	Age (yr)/Sex	14-3-3 protein	Total tau (pg/mL)	RT-QuIC*
49	56/F	Positive	16,816	P (2/4)
50	75/F	Positive	5,158	P (3/4)
51	66/M	Positive	16,734	P (4/4)
52	74/F	Positive	3,196	P (4/4)
53	71/F	Positive	3,928	P (4/4)
54	75/F	Positive	18,912	P (3/4)
55	69/M	Positive	4,174	P (4/4)
56	78/F	Positive	14,862	N (0/4)
57	47/F	Positive	5,840	N (0/4)
58	69/M	Positive	21,170	P (4/4)
59	69/M	Positive	11,721	N (0/4)
60	71/M	Positive	709	N (0/4)
61	75/F	Positive	115	P (1/4)
62	82/F	Positive	3,710	N (0/4)
63	71/F	Positive	1,234	N (0/4)
64	78/M	Positive	2,107	P (3/4)
65	63/M	Positive	3,402	P (3/4)
66	67/F	Positive	7,048	P (4/4)
67	64/M	Positive	3,491	P (3/4)
68	68/F	Positive	9,033	P (4/4)
69	57/M	Positive	14,643	P (4/4)
70	68/F	Positive	2,923	P (2/4)
71	70/F	Positive	10,265	P (4/4)
72	58/M	Positive	23,071	P (4/4)
73	67/F	Positive	2,141	N (0/4)
74	54/F	Positive	20,830	P (1/4)
75	54/F	Positive	3,025	P (4/4)
76	65/M	Positive	445	P (1/4)
77	81/M	Positive	8,651	P (4/4)
78	86/M	Positive	17,473	P (4/4)
79	59/F	Positive	9,935	P (4/4)
80	53/F	Positive	7,413	P (3/4)
81	65/F	Positive	895	P (1/4)
Number of samples with positive reactions/total number of samples				62/81 (76.5%)

*After checking 14-3-3 protein's level, RT-QuIC reaction was performed using the CSF specimens of definite or probable sCJD patients in the Republic of Korea (37 females and 44 males; aged 27–86). CSF with at least one positive reaction of quadruplicate was defined as positive in the RT-QuIC reaction. The levels of total tau in CSF have been used as a biomarker for the diagnosis of CJD (total tau >1,400 pg/mL).¹⁴ 1–12: patients in 2010, 13–24: patients in 2011, 25–44: patients in 2012, 45–65: patients in 2013, 66–81: patients in 2014.

CJD: Creutzfeldt-Jakob disease, CSF: cerebrospinal fluid, N: negative reaction, P: positive reaction, RT-QuIC: real-time quaking-induced conversion, sCJD: sporadic CJD.